18F-PSMA-1007 PET/CT在甲状腺髓样癌患者中的前瞻性探索性研究
这项前瞻性可行性研究纳入8例甲状腺髓样癌(MTC)患者,比较18F-PSMA-1007 PET/CT与18F-FDG PET/CT的诊断效能。结果显示18F-PSMA-1007 PET/CT在患者水平敏感度为88%,病灶水平敏感度为45%,与18F-FDG PET/CT(46%)无显著差异;但部分病灶SUVpeak较高,可能提示177Lu-PSMA-617治疗的候选者。
要点
- 18F-PSMA-1007 PET/CT在MTC患者中患者水平敏感度为88%,病灶水平敏感度为45%。
- 与18F-FDG PET/CT相比,病灶检出敏感度无显著差异(45% vs 46%,p=0.893)。
- 18F-PSMA-1007高摄取病灶可能筛选177Lu-PSMA-617治疗候选者。
核心结论
- 在MTC患者中,18F-PSMA-1007 PET/CT评估疾病范围的价值有限,与现有影像模态相比分期价值似乎有限。
- 部分病灶高摄取(超过肝脏)可能识别177Lu-PSMA-617治疗的潜在候选者,需进一步研究。
研究设计与样本
- 前瞻性、探索性可行性研究,纳入8例组织病理学确诊的MTC患者,年龄≥18岁,降钙素/CEA升高,且有临床指征行18F-FDG PET/CT。
- 以复合参考标准(CRS)为参照,在患者、区域(颈部/胸部/腹部/骨骼)和病灶水平分析18F-PSMA-1007 PET/CT与18F-FDG PET/CT的诊断效能。
主要发现
- CRS共识别186个肿瘤病灶;患者水平敏感度18F-PSMA-1007 PET/CT为88%,18F-FDG PET/CT为100%。
- 32个评估区域中16个(50%)为肿瘤阳性,18F-PSMA-1007 PET/CT和18F-FDG PET/CT分别正确识别12个(敏感度75%)和14个(敏感度88%)。
- 病灶水平18F-PSMA-1007 PET/CT检出84个病灶(敏感度45%),18F-FDG PET/CT检出85个(敏感度46%),p=0.893。
- 病灶半定量分析显示18F-PSMA-1007的SUVpeak为3.37(范围1.78–9.63),高于18F-FDG PET/CT的2.52(范围1.04–5.51),p<0.001。
临床怎么用
- 18F-PSMA-1007 PET/CT在MTC分期中的价值有限,不应常规替代18F-FDG PET/CT。
- 对于18F-PSMA-1007高摄取(超过肝脏)的病灶,可考虑评估177Lu-PSMA-617治疗的可行性。
局限性
- 探索性、假设生成性研究,样本量小(8例患者)。
- 结果需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Prostate specific membrane antigen (PSMA) is expressed in the neo-vasculature of most medullary thyroid carcinomas (MTCs) and can be imaged with PET/CT. This prospective, feasibility study evaluated the diagnostic performance of 18F-PSMA-1007 PET/CT in MTC patients compared to 18F-FDG PET/CT. METHODS: Eligible patients were ≥ 1 18 years, had histopathologically confirmed MTC, elevated calcitonin/CEA, and a clinically indicated 18F-FDG PET/CT. All imaging ≤ 1 year prior was reviewed to establish a composite reference standard (CRS) of total tumor lesions. Analyses were performed at patient, region (neck/thorax/abdomen/bone), and lesion level. Lesions were also semi-quantified using SUVpeak. RESULTS: In eight included patients, the CRS identified 186 tumor lesions. Patient-based sensitivity of 18F-PSMA-1007 PET/CT was 88% (median lesion per patient 3, range 2 – 51), while 100% for 18F-FDG PET/CT (lesions per patient 5, range 2 – 45). Of 32 evaluated regions, 16 (50%) were tumor positive, of which 18F-PSMA-1007 PET/CT and 18F-FDG PET/CT identified 12 (sensitivity 75%), and 14 (sensitivity 88%) correctly, respectively. 18F-PSMA-1007 PET/CT detected 84 lesions (sensitivity 45%) while the 18F-FDG PET/CT detected 85 (sensitivity 46%) of 186 tumor lesions (p = 0.893). Lesion-based semi-quantitative analysis identified a higher SUVpeak on 18F-PSMA-1007 (18F-PSMA-1007 3.37 (range 1.78 – 9.63) vs 18F-FDG PET/CT 2.52 (range 1.04 – 5.51) p < 0.001). CONCLUSION: In this exploratory, hypothesis-generating study, 18F-PSMA-1007 PET/CT shows modest utility in assessing disease extent in MTC patients. Its value in staging therefore seems limited when compared to existing imaging modalities. Nonetheless, high tracer uptake (exceeding the liver) in selected lesions might identify possible candidates for 177Lu-PSMA-617 therapy, warranting further research.
引用
- Jager EC, Kruijff S, Kloet RW, et al. A prospective, exploratory study of 18F-PSMA-1007 PET/CT in patients with medullary thyroid cancer. Eur J Nucl Med Mol Imaging. 2026. PMID: 42020810. doi:10.1007/s00259-026-07902-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。